Cellebrite DI Ltd. $CLBT Stock Position Lowered by Axon Enterprise Inc.

Axon Enterprise Inc. reduced its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 59.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,509,341 shares of the company’s stock after selling 2,170,034 shares during the quarter. Cellebrite DI comprises 100.0% of Axon Enterprise Inc.’s investment portfolio, making the stock its biggest position. Axon Enterprise Inc. owned about 0.63% of Cellebrite DI worth $27,213,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock worth $3,362,000 after purchasing an additional 24,881 shares in the last quarter. Geode Capital Management LLC lifted its stake in Cellebrite DI by 16.2% in the 2nd quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after purchasing an additional 43,898 shares in the last quarter. Invesco Ltd. lifted its stake in Cellebrite DI by 6.4% in the 2nd quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after purchasing an additional 209,473 shares in the last quarter. First Trust Advisors LP purchased a new stake in Cellebrite DI in the 2nd quarter worth approximately $341,000. Finally, Marshall Wace LLP purchased a new stake in Cellebrite DI in the 2nd quarter worth approximately $4,472,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Stock Performance

Cellebrite DI stock opened at $12.47 on Thursday. The firm’s fifty day moving average price is $13.15 and its 200-day moving average price is $14.95. The stock has a market cap of $3.11 billion, a P/E ratio of 44.54, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Analyst Ratings Changes

Several research firms have issued reports on CLBT. DA Davidson began coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC lowered their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 13,269 shares of company stock worth $169,592. Company insiders own 5.70% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.